Bioxytran Valuation
| BIXT Stock | USD 0.09 0.01 12.92% |
Bioxytran seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Bioxytran from analyzing the firm fundamentals such as Shares Outstanding of 144.64 M, price to sales of 532.56 X, and Return On Asset of -7.04 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Bioxytran's price fluctuation is out of control at this time. Calculation of the real value of Bioxytran is based on 3 months time horizon. Increasing Bioxytran's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bioxytran otc stock is determined by what a typical buyer is willing to pay for full or partial control of Bioxytran. Since Bioxytran is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bioxytran OTC Stock. However, Bioxytran's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.09 | Real 0.0666 | Hype 0.09 | Naive 0.11 |
The intrinsic value of Bioxytran's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bioxytran's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bioxytran helps investors to forecast how Bioxytran otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bioxytran more accurately as focusing exclusively on Bioxytran's fundamentals will not take into account other important factors: Bioxytran Total Value Analysis
Bioxytran is currently anticipated to have valuation of 19.06 M with market capitalization of 17.21 M, debt of 2.17 M, and cash on hands of 500.68 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bioxytran fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
19.06 M | 17.21 M | 2.17 M | 500.68 K |
Bioxytran Asset Utilization
One of the ways to look at asset utilization of Bioxytran is to check how much profit was generated for every dollar of assets it reports. Bioxytran shows a negative utilization of assets of -7.04 percent, losing $0.0704 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bioxytran shows how discouraging it operates for each dollar spent on its assets.Bioxytran Ownership Allocation
Bioxytran holds a total of 144.64 Million outstanding shares. Bioxytran shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.6 percent of Bioxytran outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bioxytran Profitability Analysis
Net Loss for the year was (4.04 M) with profit before overhead, payroll, taxes, and interest of 0.About Bioxytran Valuation
The otc valuation mechanism determines Bioxytran's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Bioxytran based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bioxytran. We calculate exposure to Bioxytran's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bioxytran's related companies.Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Bioxytran operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
8 Steps to conduct Bioxytran's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Bioxytran's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bioxytran's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bioxytran's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bioxytran's revenue streams: Identify Bioxytran's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bioxytran's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bioxytran's growth potential: Evaluate Bioxytran's management, business model, and growth potential.
- Determine Bioxytran's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bioxytran's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Bioxytran OTC Stock Analysis
When running Bioxytran's price analysis, check to measure Bioxytran's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioxytran is operating at the current time. Most of Bioxytran's value examination focuses on studying past and present price action to predict the probability of Bioxytran's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioxytran's price. Additionally, you may evaluate how the addition of Bioxytran to your portfolios can decrease your overall portfolio volatility.